Obetix 5 MG (Obeticholic Acid)

PBC in Combination with UDCA (Second-Line Therapy)

Obetix 5 MG is indicated for adult patients with Primary Biliary Cholangitis (PBC) who have not achieved an adequate biochemical response to an appropriate dose of ursodeoxycholic acid (UDCA) after at least 12 months of therapy. Approximately 40% of PBC patients fail to reach adequate ALP and bilirubin targets on UDCA alone, placing them at elevated risk of disease progression, liver failure, and the need for liver transplantation. Obetix is added to the existing UDCA regimen without dose adjustment of UDCA.

PBC as Monotherapy (UDCA-Intolerant Patients)

For adult patients with PBC who are unable to tolerate UDCA due to adverse effects, Obetix 5 MG is approved as a standalone monotherapy. UDCA intolerance which may manifest as abdominal discomfort, diarrhoea, alopecia, or worsening pruritus affects a subset of PBC patients who nonetheless require active disease-modifying treatment to prevent biliary progression. In this population, Obetix delivers direct FXR-mediated bile acid regulation and anti-fibrotic protection as the sole systemic therapy.

Biochemical Disease Activity Reduction

The therapeutic goal of Obetix in PBC is a reduction in alkaline phosphatase (ALP) to below 1.67 times the upper limit of normal with at least a 15% reduction from baseline, alongside normalisation of total bilirubin. These biochemical targets are validated surrogate endpoints shown to correlate with reduced long-term risk of liver failure, need for liver transplantation, and premature mortality in PBC. In the POISE trial, Ocaliva 5–10mg (titration arm) achieved this composite endpoint in 46% of patients versus 10% with placebo (p<0.001).

Prevention of Disease Progression in PBC

Left untreated or inadequately controlled, PBC leads to biliary cirrhosis, portal hypertension, oesophageal varices, ascites, and liver failure requiring transplantation. Obetix, by normalising bile acid homeostasis and reducing hepatic inflammation and fibrosis, addresses the pathological cascade that drives PBC progression. The 5-year POISE open-label extension demonstrated that biochemical improvements in ALP were sustained over time, with total bilirubin levels remaining stable a key predictor of long-term hepatic function and transplant-free survival in PBC.

World’s First Approved FXR Agonist

Obeticholic Acid is the first-in-class FXR agonist approved for clinical use globally a novel mechanism entirely distinct from UDCA and all prior PBC treatments. Its development was recognised with USFDA Orphan Drug Designation, Fast Track Designation, and Breakthrough Therapy Designation, reflecting its significant clinical unmet need and therapeutic innovation in a rare, life-limiting liver disease.

POISE Trial Proven Biochemical Efficacy

In the pivotal Phase III POISE trial (published in the New England Journal of Medicine), the titration regimen of Obeticholic Acid (5mg titrated to 10mg) achieved the composite ALP/bilirubin primary endpoint in 46% of patients versus 10% in the placebo arm (p<0.001). ALP reductions of −113 U/L (titration arm) were observed as early as two weeks and maintained at every subsequent time point a clinically meaningful reduction in the biomarker most closely associated with PBC prognosis and transplant risk.

5-Year POISE Extension Durable Long-Term Response

The 5-year POISE open-label extension (193 patients) confirmed that biochemical improvements in ALP were sustained over long-term treatment, with total bilirubin levels remaining stable or improving providing hepatologists with confidence in the durability of FXR agonism as a core component of long-term PBC disease management beyond 12 months.

Protective Titration Strategy 5mg Start

The approved starting dose of 5mg once daily is specifically designed to minimise pruritus the most common dose-dependent adverse effect of FXR agonists. Discontinuation rates due to pruritus in the titration arm (starting at 5mg) were just 1%, compared with 10% when treatment was initiated directly at 10mg demonstrating that the 5mg initiation strategy protects tolerability without sacrificing long-term efficacy.

Complementary Mechanism to UDCA

Obetix and UDCA act through entirely different and complementary mechanisms UDCA works by hydrophilising and displacing toxic bile acids, while Obetix activates FXR to reduce bile acid synthesis and enhance biliary excretion. This mechanistic complementarity means their combination produces additive therapeutic benefits in UDCA partial-responders that neither agent alone achieves.

Affordable Generic Alternative to Ocaliva

Obetix contains the same active ingredient as Ocaliva (Intercept Pharmaceuticals) in the same 5mg film-coated tablet form, manufactured by Beacon Pharmaceuticals Ltd. under WHO-GMP and cGMP standards. For patients in lower- and middle-income countries who cannot access Ocaliva at its originator price, Obetix provides a high-quality, bioequivalent, and significantly more affordable treatment option for a lifelong chronic liver disease.

Common Side Effects

Pruritus (cholestatic itch) the most common adverse effect; dose-dependent and most frequent during the first months of treatment. Reported in 56% of patients in the POISE titration arm versus 38% on placebo; severe pruritus in approximately 20% of treated patients.

Fatigue

Abdominal pain and discomfort

Constipation

Rash and eczema

Dyslipdaemia Obeticholic Acid may reduce HDL cholesterol and increase LDL cholesterol; monitor lipid panel regularly

Oropharyngeal pain

Dizziness

Arthralgia

Thyroid function abnormality monitor thyroid function periodically during treatment

Serious Warnings and Precautions

Contraindicated in decompensated cirrhosis (Child-Pugh Class B or C) or prior decompensation event at the standard once-daily dose. Use in these patients requires a reduced weekly dosing schedule under specialist supervision.

Liver-related adverse events including jaundice, worsening ascites, and PBC flare observed in patients receiving doses above the recommended level. A dose-response relationship for hepatic adverse events was confirmed in clinical studies; strict adherence to the approved dosing regimen is essential.

Biliary obstruction Obetix must be stopped and the obstruction relieved before treatment is restarted. Obeticholic Acid must not be given to patients with complete biliary obstruction.

Dyslipidaemia monitor lipid profiles throughout treatment. Consider lipid-lowering therapy if clinically significant LDL elevation occurs, bearing in mind potential interactions with bile acid sequestrants used to manage pruritus.

Oesophageal varices and ascites observed as hepatic adverse events in the POISE 3-year interim analysis. Regular monitoring for clinical signs of portal hypertension is recommended throughout treatment.

Limited human data in pregnancy and lactation. Use with caution; the potential risk to the foetus and nursing infant is unknown. Consult the prescribing physician before starting Obetix if pregnant or breastfeeding.

If bile acid sequestrants (cholestyramine, colesevelam, or colestipol) are used to manage pruritus, take Obetix at least 4 to 6 hours before or after the sequestrant, as these agents may reduce Obeticholic Acid absorption.